PharmaNet Development Group has been selected to conduct and manage Scancell Ltd.’s Phase I/II trial with SCIB1 scheduled for 1H10. SCIB1 is a DNA ImmunoBody vaccine for the treatment of melanoma. David Evans, chairman of Scancell, commented, “We are delighted to have selected PharmaNet to manage Scancell’s Phase I/II trial program with SCIB1. PharmaNet’s extensive experience, particularly in the management of early stage oncology clinical trials, will be of critical importance to Scancell a...